Fidelity Investments
OBIO icon

Fidelity Investments’s Orchestra BioMed OBIO Stock Holding History

Fidelity Investments’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14K Sell
265
-17,811
-99% -$72.8K ﹤0.01% 5220
2026
Q1 		$76.8K Buy
+18,076
New +$77K ﹤0.01% 3913
2025
Q3 		– Sell
-1,646
Closed -$4.41K – 5516
2025
Q2 		$4.41K Buy
1,646
+550
+50% +$1.6K ﹤0.01% 4735
2025
Q1 		$4.69K Buy
1,096
+89
+9% +$442 ﹤0.01% 4725
2024
Q4 		$4.03K Sell
1,007
-1,868
-65% -$10K ﹤0.01% 4709
2024
Q3 		$14.8K Buy
2,875
+2,419
+530% +$15.8K ﹤0.01% 4301
2024
Q2 		$3.72K Sell
456
-346
-43% -$2K ﹤0.01% 4622
2024
Q1 		$4.23K Sell
802
-2,547
-76% -$17.3K ﹤0.01% 4555
2023
Q4 		$30.6K Buy
3,349
+1,083
+48% +$7.39K ﹤0.01% 3741
2023
Q3 		$19.8K Buy
2,266
+1,889
+501% +$12.7K ﹤0.01% 3807
2023
Q2 		$2.64K Buy
+377
New +$5.72K ﹤0.01% 4524

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Fidelity Investments's OBIO Position: Q2 2026 in Review

Fidelity Investments reduced its Orchestra BioMed (OBIO) stake by 99% in Q2 2026, selling an estimated $72.8K and leaving 265 shares worth $1.14K. The position accounts for ﹤0.01% of the portfolio, ranked #5220.

Fidelity Investments first reported a position in OBIO in Q2 2023 and has held it in 11 quarters since. The position peaked at $76.8K in Q1 2026. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Fidelity Investments held 265 shares of Orchestra BioMed worth $1.14K as of Q2 2026.
  • Fidelity Investments sold 17,811 Orchestra BioMed shares in Q2 2026, an estimated $72.8K.
  • Orchestra BioMed made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #5220 holding.
  • Fidelity Investments first reported a position in Orchestra BioMed in Q2 2023 and has held it in 11 quarters since.
  • Fidelity Investments's Orchestra BioMed position peaked at $76.8K in Q1 2026.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.